|
業務類別
|
Biotechnology |
|
業務概覽
|
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, theinevitable loss of near vision that impacts the daily lives of nearly all people over 45. |
| 公司地址
| 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075 |
| 電話號碼
| +1 858 925-7000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.lenz-tx.com |
| 員工數量
| 42 |
| Mr. Daniel R. Chevallard |
Chief Financial Officer and Principal Accounting Officer |
美元 376.81K |
28/04/2025 |
| Mr. Evert B. Schimmelpennink |
Director, President, Chief Executive Officer and Secretary |
美元 607.13K |
28/04/2025 |
| Mr. Shawn Olsson |
Chief Commercial Officer |
-- |
28/04/2025 |
| Dr. Marc Odrich, M.D. |
Chief Medical Officer |
美元 466.25K |
28/04/2025 |
|
|
| Ms. Shelley B. Thunen |
Independent Director |
28/04/2025 |
| Dr. Kimberlee Cobleigh Drapkin, PhD |
Independent Director |
28/04/2025 |
| Mr. Jeffrey P. George |
Chairperson of the Board |
28/04/2025 |
| Mr. Evert B. Schimmelpennink |
Director, President, Chief Executive Officer and Secretary |
28/04/2025 |
| Dr. Zachary Scheiner, PhD |
Independent Director |
28/04/2025 |
| Dr. Frederic Guerard, Pharm.D. |
Independent Director |
28/04/2025 |
| Mr. James McCollum, M.D. |
Independent Director |
28/04/2025 |
|
|
|
|
